Invasive fungal infection in haematopoietic stem cell transplant recipients: Epidemiology from the transplant physician's viewpoint

Mycopathologia

Volumn 168, Issue 6, 2009, Pages 283-297

  Bow, E J ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Allogeneic; Autologous; Epidemiology; Fungal; Infection; Invasive fungal infection; Practice patterns; Risk; Stem cell transplant

Indexed keywords

ANTIFUNGAL AGENT;

ARTICLE; DEUTEROMYCETES; DRUG EFFECT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MYCOSIS; NEUTROPENIA; PHYSICIAN; RISK FACTOR;

ANTIFUNGAL AGENTS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; MITOSPORIC FUNGI; MYCOSES; NEUTROPENIA; PHYSICIANS; RISK FACTORS;

CYTOMEGALOVIRUS;

EID: 71449128002     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-009-9196-6     Document Type: Article

References (131)

1. Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua A. EBMT activity survey 2004 and changes in disease indication over the past 15 years. Bone Marrow Transplant. 2006; 37(12): 1069-85. doi: 10. 1038/sj. bmt. 1705377.
2. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003; 102(2): 756-62. doi: 10. 1182/blood-2002-08-2628.
3. Diaconescu R, Flowers CR, Storer B, et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood. 2004; 104(5): 1550-8. doi: 10. 1182/blood-2004-03-0804.
4. Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood. 2004; 104(4): 961-8. doi: 10. 1182/blood-2004-02-0545.
5. Davison GM, Novitzky N, Kline A, et al. Immune reconstitution after allogeneic bone marrow transplantation depleted of T cells. Transplantation. 2000; 69(7): 1341-7. doi: 10. 1097/00007890-200004150-00022.
6. Inoue H, Yasuda Y, Hattori K, et al. The kinetics of immune reconstitution after cord blood transplantation and selected CD34+ stem cell transplantation in children: comparison with bone marrow transplantation. Int J Hematol. 2003; 77(4): 399-407. doi: 10. 1007/BF02982652.
7. Martinez C, Urbano-Ispizua A, Rozman C, et al. Immune reconstitution following allogeneic peripheral blood progenitor cell transplantation: comparison of recipients of positive CD34+ selected grafts with recipients of unmanipulated grafts. Exp Hematol. 1999; 27(3): 561-8. doi: 10. 1016/S0301-472X(98)00029-0.
8. Watanabe T, Kawano Y, Watanabe A, Takaue Y. Autologous and allogeneic transplantation with peripheral blood CD34+ cells: a pediatric experience. Haematologica. 1999; 84(2): 167-76.
9. Bhatti Z, Shaukat A, Almyroudis NG, Segal BH. Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients. Mycopathologia. 2006; 162(1): 1-15. doi: 10. 1007/s11046-006-0025-x.
10. Marr KA. Fungal infections in hematopoietic stem cell transplant recipients. Med Mycol. 2008; 46(4): 293-302. doi: 10. 1080/13693780701885552.
11. Shaukat A, Bakri F, Young P, et al. Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: clinical, radiologic, and pathologic characteristics. Mycopathologia. 2005; 159(2): 181-8. doi: 10. 1007/s11046-004-5495-0.
12. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002; 100(13): 4358-66. doi: 10. 1182/blood-2002-05-1496.
13. Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood. 2003; 102(3): 827-33. doi: 10. 1182/blood-2003-02-0456.
14. Jantunen E, Ruutu P, Niskanen L, et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant. 1997; 19(8): 801-8. doi: 10. 1038/sj. bmt. 1700737.
15. Jantunen E, Salonen J, Juvonen E, et al. Invasive fungal infections in autologous stem cell transplant recipients: a nation-wide study of 1188 transplanted patients. Eur J Haematol. 2004; 73(3): 174-8. doi: 10. 1111/j. 1600-0609. 2004. 00273. x.
16. Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis. 2008; 47(8): 1041-50. doi: 10. 1086/591969.
17. Opal SM, Asp AA, Cannady PB, Morse PL, Burton LJ, Hammer PG. Efficacy of infection control measures during a nosocomial outbreak of disseminated aspergillosis associated with hospital construction. J Infect Dis. 1986; 153(3): 634-7.
18. Alberti C, Bouakline A, Ribaud P, et al. Relationship between environmental fungal contamination and the incidence of invasive aspergillosis in haematology patients. J Hosp Infect. 2001; 48(3): 198-206. doi: 10. 1053/jhin. 2001. 0998.
19. Sherertz RJ, Belani A, Kramer BS. Impact of air filtration on nosocomial Aspergillus infections. Unique risk of bone marrow transplant recipients. Am J Med. 1987; 83(4): 709-18. doi: 10. 1016/0002-9343(87)90902-8.
20. Eckmanns T, Ruden H, Gastmeier P. The influence of high-efficiency particulate air filtration on mortality and fungal infection among highly immunosuppressed patients: a systematic review. J Infect Dis. 2006; 193(10): 1408-18. doi: 10. 1086/503435.
21. Centers for Disease Control and Prevention. Guidelines for prevention of nosocomial pneumonia. MMWR Recomm Rep. 1997; 46: 1-79.
22. Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep. 2000; 49(RR-10): 1-7.
23. Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R. Guidelines for preventing health-care-associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep. 2004; 53(RR-3): 1-36.
24. Sehulster L, Chinn RY. Guidelines for environmental infection control in health-care facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep. 2003; 52: 1-42.
25. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992; 326(13): 845-51.
26. Reich G, Mapara MY, Reichardt P, Dorken B, Maschmeyer G. Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors. Bone Marrow Transplant. 2001; 27(5): 525-9. doi: 10. 1038/sj. bmt. 1702822.
27. Junghanss C, Marr KA, Carter RA, et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant. 2002; 8(9): 512-20. doi: 10. 1053/bbmt. 2002. v8. pm12374456.
28. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007; 356(4): 335-47. doi: 10. 1056/NEJMoa061098.
29. Martino R, Subira M, Rovira M, et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol. 2002; 116(2): 475-82. doi: 10. 1046/j. 1365-2141. 2002. 03259. x.
30. Pagano L, Caira M, Nosari A, et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study-Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis. 2007; 45(9): 1161-70. doi: 10. 1086/522189.
31. Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect. 2004; 10(Suppl 1): 48-66. doi: 10. 1111/j. 1470-9465. 2004. 00839. x.
32. Morgan J, Wannemuehler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol. 2005; 43(Suppl 1): S49-58. doi: 10. 1080/13693780400020113.
33. Pfaller MA, Pappas PG, Wingard JR. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis. 2006; 43(Suppl 1): S3-14. doi: 10. 1086/504490.
34. Blijlevens NM, Donnelly JP, De Pauw BE. Impaired gut function as risk factor for invasive candidiasis in neutropenic patients. Br J Haematol. 2002; 117(2): 259-64. doi: 10. 1046/j. 1365-2141. 2002. 03394. x.
35. Pagano L, Antinori A, Ammassari A, et al. Retrospective study of candidemia in patients with hematological malignancies clinical features, risk factors and outcome of 76 episodes. Eur J Haematol. 1999; 63(2): 77-85.
36. Richet H, Roux P, Des CC, Esnault Y, Andremont A. Candidemia in French hospitals: incidence rates and characteristics. Clin Microbiol Infect. 2002; 8(7): 405-12. doi: 10. 1046/j. 1469-0691. 2002. 00446. x.
37. Viudes A, Peman J, Canton E, Ubeda P, Lopez-Ribot JL, Gobernado M. Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur J Clin Microbiol Infect Dis. 2002; 21(11): 767-74. doi: 10. 1007/s10096-002-0822-1.
38. Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer. 2008; 112(11): 2493-9. doi: 10. 1002/cncr. 23466.
39. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004; 103(4): 1527-33. doi: 10. 1182/blood-2003-08-2644.
40. Nucci M, Marr KA. Emerging fungal diseases. Clin Infect Dis. 2005; 41(4): 521-6. doi: 10. 1086/432060.
41. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005; 41(5): 634-53. doi: 10. 1086/432579.
42. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. 1999; 340(10): 764-71. doi: 10. 1056/NEJM199903113401004.
43. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002; 346(4): 225-34. doi: 10. 1056/NEJM200201243460403.
44. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004; 351(14): 1391-402. doi: 10. 1056/NEJMoa040446.
45. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007; 356(4): 348-59. doi: 10. 1056/NEJMoa061094.
46. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol. 2004; 42(7): 3142-6. doi: 10. 1128/JCM. 42. 7. 3142-3146. 2004.
47. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol. 2004; 42(10): 4419-31. doi: 10. 1128/JCM. 42. 10. 4419-4431. 2004.
48. Atkinson BJ, Lewis RE, Kontoyiannis DP. Candida lusitaniae fungemia in cancer patients: risk factors for amphotericin B failure and outcome. Med Mycol. 2008; 17: 1-6.
49. Yoon SA, Vazquez JA, Steffan PE, Sobel JD, Akins RA. High-frequency, in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance. Antimicrob Agents Chemother. 1999; 43(4): 836-45.
50. Guarro J, Kantarcioglu AS, Horre R, et al. Scedosporium apiospermum: changing clinical spectrum of a therapy-refractory opportunist. Med Mycol. 2006; 44(4): 295-327. doi: 10. 1080/13693780600752507.
51. Troke P, Aguirrebengoa K, Arteaga C, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother. 2008; 52(5): 1743-50. doi: 10. 1128/AAC. 01388-07.
52. Caira M, Girmenia C, Valentini CG, et al. Scedosporiosis in patients with acute leukemia: a retrospective multicenter report. Haematologica. 2008; 93(1): 104-10. doi: 10. 3324/haematol. 11740.
53. Nucci M, Marr KA, Queiroz-Telles F, et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2004; 38(9): 1237-42. doi: 10. 1086/383319.
54. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003; 36(9): 1122-31. doi: 10. 1086/374557.
55. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008; 47(4): 503-9. doi: 10. 1086/590004.
56. Peel T, Daffy J, Thursky K, Stanley P, Buising K. Posaconazole as first line treatment for disseminated zygomycosis. Mycoses. 2008; 51: 542-5.
57. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med. 1984; 100(3): 345-51.
58. Goodrich JM, Reed EC, Mori M, et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis. 1991; 164: 731-40.
59. Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis. 1999; 28(2): 331-40. doi: 10. 1086/515128.
60. Gratwohl A, Baldomero H, Passweg J, Urbano-Ispizua A. Increasing use of reduced intensity conditioning transplants: report of the 2001 EBMT activity survey. Bone Marrow Transplant. 2002; 30(12): 813-31. doi: 10. 1038/sj. bmt. 1703819.
61. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med. 2001; 344(3): 175-81. doi: 10. 1056/NEJM200101183440303.
62. Couban S, Simpson DR, Barnett MJ, et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood. 2002; 100(5): 1525-31. doi: 10. 1182/blood-2002-01-0048.
63. Ringden O, Labopin M, Gorin NC, et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2004; 22(3): 416-23. doi: 10. 1200/JCO. 2004. 06. 102.
64. Schmitz N, Linch DC, Dreger P, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet. 1996; 347: 353-7. doi: 10. 1016/S0140-6736(96)90536-X.
65. D'Antonio D, Iacone A, Pierelli L, Bonfini T. Patterns of recovery phase infection after autologous blood progenitor cell transplantation in patients with malignancies. The Gruppo Italiano di Studio per la Manipolazione Cellulare in Ematologia. Eur J Clin Microbiol Infect Dis. 1995; 14(6): 552-6. doi: 10. 1007/BF02113440.
66. Ringden O, Barrett AJ, Zhang MJ, et al. Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. Br J Haematol. 2003; 121(6): 874-85. doi: 10. 1046/j. 1365-2141. 2003. 04364. x.
67. Bittencourt H, Rocha V, Chevret S, et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood. 2002; 99(8): 2726-33. doi: 10. 1182/blood. V99. 8. 2726.
68. Beguin Y, Baudoux E, Sautois B, et al. Hematopoietic recovery in cancer patients after transplantation of autologous peripheral blood CD34+ cells or unmanipulated peripheral blood stem and progenitor cells. Transfusion. 1998; 38(2): 199-208. doi: 10. 1046/j. 1537-2995. 1998. 38298193106. x.
69. Gribben JG. Tumor contamination of stem cell products, the role of purging. In: Stoiffer RJ, editor. Stem cell transplantation for hematological malignancies. Totawa, New Jersey: Humana Press; 2004. p. 417-29.
70. Crippa F, Holmberg L, Carter RA, et al. Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2002; 8(5): 281-9. doi: 10. 1053/bbmt. 2002. v8. pm12064366.
71. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002; 34(7): 909-17. doi: 10. 1086/339202.
72. Frere P, Pereira M, Fillet G, Beguin Y. Infections after CD34-selected or unmanipulated autologous hematopoietic stem cell transplantation. Eur J Haematol. 2006; 76(2): 102-8. doi: 10. 1111/j. 1600-0609. 2005. 00569. x.
73. Smith TJ, Khatcheressian J, Lyman GH, et al. update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006; 24(19): 3187-205. doi: 10. 1200/JCO. 2006. 06. 4451.
74. McQuaker IG, Hunter AE, Pacey S, Haynes AP, Iqbal A, Russell NH. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. J Clin Oncol. 1997; 15(2): 451-7.
75. Stinson TJ, Adams JR, Bishop MR, Kruse S, Tarantolo S, Bennet CL. Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantation. Bone Marrow Transplant. 2000; 26(6): 663-6. doi: 10. 1038/sj. bmt. 1702579.
76. Auner HW, Sill H, Mulabecirovic A, Linkesch W, Krause R. Infectious complications after autologous hematopoietic stem cell transplantation: comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma. Ann Hematol. 2002; 81(7): 374-7. doi: 10. 1007/s00277-002-0484-1.
77. Salazar R, Sola C, Maroto P, et al. Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999; 23(1): 27-33. doi: 10. 1038/sj. bmt. 1701520.
78. Sezer O, Eucker J, Bauhuis C, et al. Patients with malignant lymphomas experience a higher rate of documented infections than patients with breast cancer after high-dose chemotherapy with autologous peripheral stem cell transplantation. Ann Hematol. 2000; 79(11): 627-30. doi: 10. 1007/s002770000218.
79. Celebi H, Akan H, Akcaglayan E, Ustun C, Arat M. Febrile neutropenia in allogeneic and autologous peripheral blood stem cell transplantation and conventional chemotherapy for malignancies. Bone Marrow Transplant. 2000; 26(2): 211-4. doi: 10. 1038/sj. bmt. 1702503.
80. Kolbe K, Domkin D, Derigs HG, Bhakdi S, Huber C, Aulitzky WE. Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation. Bone Marrow Transplant. 1997; 19(2): 143-7. doi: 10. 1038/sj. bmt. 1700621.
81. Badell I. Cytokines following SCT: indications and controversies. Bone Marrow Transplant. 2008; 41(Suppl 2): S27-9. doi: 10. 1038/bmt. 2008. 50.
82. Montesinos J, Sola C, Maroto P, et al. Fungal infections in patients with solid tumors treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Eur J Clin Microbiol Infect Dis. 2001; 20(8): 569-72. doi: 10. 1007/s100960100555.
83. Blijlevens N, Schwenkglenks M, Bacon P, et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy-European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol. 2008; 26(9): 1519-25. doi: 10. 1200/JCO. 2007. 13. 6028.
84. Wardley AM, Jayson GC, Swindell R, et al. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol. 2000; 110(2): 292-9. doi: 10. 1046/j. 1365-2141. 2000. 02202. x.
85. Bow EJ, Meddings JB. Intestinal mucosal dysfunction and infection during remission-induction therapy for acute myeloid leukaemia. Leukemia. 2006; 20(12): 2087-92. doi: 10. 1038/sj. leu. 2404440.
86. Bow EJ, Loewen R, Cheang MS, Shore TB, Rubinger M, Schacter B. Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults. J Clin Oncol. 1997; 15(6): 2254-61.
87. Tsirigotis P, Triantafyllou K, Girkas K, et al. Keratinocyte growth factor is effective in the prevention of intestinal mucositis in patients with hematological malignancies treated with high-dose chemotherapy and autologous hematopoietic SCT: a video-capsule endoscopy study. Bone Marrow Transplant. 2008; 42(5): 337-43. doi: 10. 1038/bmt. 2008. 168.
88. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004; 351(25): 2590-8. doi: 10. 1056/NEJMoa040125.
89. Langner S, Staber P, Schub N, et al. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients. Bone Marrow Transplant. 2008; 42(4): 275-9. doi: 10. 1038/bmt. 2008. 157.
90. Nasilowska-Adamska B, Rzepecki P, Manko J, et al. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant. Bone Marrow Transplant. 2007; 40(10): 983-8. doi: 10. 1038/sj. bmt. 1705846.
91. Beaven AW, Shea TC. The effect of palifermin on chemotherapyand radiation therapy-induced mucositis: a review of the current literature. Support Cancer Ther. 2007; 4(4): 188-97. doi: 10. 3816/SCT. 2007. n. 014.
92. Keefe D, Lees J, Horvath N. Palifermin for oral mucositis in the high-dose chemotherapy and stem cell transplant setting: the Royal Adelaide Hospital Cancer Centre experience. Support Care Cancer. 2006; 14(6): 580-2. doi: 10. 1007/s00520-006-0048-3.
93. Blazar BR, Weisdorf DJ, DeFor T, et al. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood. 2006; 108(9): 3216-22. doi: 10. 1182/blood-2006-04-017780.
94. Levine JE, Blazar BR, DeFor T, Ferrara JL, Weisdorf DJ. Long-term follow-up of a phase I/II randomized, placebo-controlled trial of palifermin to prevent graft-versus-host disease (GVHD) after related donor allogeneic hematopoietic cell transplantation (HCT). Biol Blood Marrow Transplant. 2008; 14(9): 1017-21. doi: 10. 1016/j. bbmt. 2008. 06. 013.
95. Maertens JA, Frere P, Lass-Florl C, Heinz W, Cornely OA. Primary antifungal prophylaxis in leukaemia patients. Eur J Cancer Suppl. 2007; 5(2): 43-8. doi: 10. 1016/j. ejcsup. 2007. 06. 006.
96. Trifilio S, Verma A, Mehta J. Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice. Bone Marrow Transplant. 2004; 33(7): 735-9. doi: 10. 1038/sj. bmt. 1704423.
97. Imataki O, Kami M, Kim SW, et al. A nationwide survey of deep fungal infections and fungal prophylaxis after hematopoietic stem cell transplantation in Japan. Bone Marrow Transplant. 2004; 33(12): 1173-9. doi: 10. 1038/sj. bmt. 1704526.
98. Hagen EA, Stern H, Porter D, et al. High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation. Clin Infect Dis. 2003; 36(1): 9-15. doi: 10. 1086/344906.
99. Mihu CN, King E, Yossepovitch O, et al. Risk factors and attributable mortality of late aspergillosis after T-cell depleted hematopoietic stem cell transplantation. Transpl Infect Dis. 2008; 10(3): 162-7. doi: 10. 1111/j. 1399-3062. 2007. 00272. x.
100. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 1997; 175(6): 1459-66.
101. Platzbecker U, Deeg HJ. Acute graft-vs-host disease. In: Stoiffer RJ, editor. Stem cell transplantation for hematological malignancies. Totawa, New Jersey: Humana Press; 2004. p. 159-84.
102. Sorror M, Maris M, Diaconescu R, Storb R. Lessened severe graft-versus-host after minitransplantations. Blood. 2005; 105(6): 2614. doi: 10. 1182/blood-2004-10-4039.
103. Maertens J, Buve K, Anaissie E. Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: counterpoint. J Natl Compr Canc Netw. 2008; 6(2): 183-9.
104. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease, other late complications of bone marrow transplantation. Semin Hematol. 1991; 28(3): 250-9.
105. Storek J, Gooley T, Siadak M, et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood. 1997; 90(12): 4705-9.
106. Anderson D, DeFor T, Burns L, et al. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections. Biol Blood Marrow Transplant. 2003; 9(1): 52-9. doi: 10. 1053/bbmt. 2003. 50000.
107. Safdar A, Rodriguez GH, De Lima MJ, et al. Infections in 100 cord blood transplantations: spectrum of early and late posttransplant infections in adult and pediatric patients 1996-2005. Medicine. 2007; 86(6): 324-33.
108. Korngold R, Marini JC, de Baca ME, Murphy GF, Giles-Komar J. Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses. Biol Blood Marrow Transplant. 2003; 9(5): 292-303. doi: 10. 1016/S1083-8791(03)00087-9.
109. Marty FM, Lee SJ, Fahey MM, et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood. 2003; 102(8): 2768-76. doi: 10. 1182/blood-2003-01-0267.
110. Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc. 2008; 83(2): 181-94. doi: 10. 4065/83. 2. 181.
111. Jacobsohn DA, Hallick J, Anders V, McMillan S, Morris L, Vogelsang GB. Infliximab for steroid-refractory acute GVHD: a case series. Am J Hematol. 2003; 74(2): 119-24. doi: 10. 1002/ajh. 10392.
112. Levine JE, Paczesny S, Mineishi S, et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood. 2008; 111(4): 2470-5. doi: 10. 1182/blood-2007-09-112987.
113. Uberti JP, Ayash L, Ratanatharathorn V, et al. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant. 2005; 11(9): 680-7. doi: 10. 1016/j. bbmt. 2005. 05. 009.
114. Couriel D, Saliba R, Hicks K, et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood. 2004; 104(3): 649-54. doi: 10. 1182/blood-2003-12-4241.
115. Yamane T, Yamamura R, Aoyama Y, et al. Infliximab for the treatment of severe steroid refractory acute graft-versus-host disease in three patients after allogeneic hematopoietic transplantation. Leuk Lymphoma. 2003; 44(12): 2095-7. doi: 10. 1080/1042819031000123483.
116. Hamadani M, Hofmeister CC, Jansak B, et al. Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation. Biol Blood Marrow Transplant. 2008; 14(7): 783-9. doi: 10. 1016/j. bbmt. 2008. 04. 006.
117. Perales MA, Ishill N, Lomazow WA, et al. Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease. Bone Marrow Transplant. 2007; 40(5): 481-6. doi: 10. 1038/sj. bmt. 1705762.
118. Blaise D, Kuentz M, Fortanier C, et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol. 2000; 18(3): 537-46.
119. Amadori S, Suciu S, Jehn U, et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood. 2005; 106(1): 27-34. doi: 10. 1182/blood-2004-09-3728.
120. Majolino I, Saglio G, Scimè R, et al. High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Bone Marrow Transplant. 1996; 17: 555-60.
121. Miceli MH, Dong L, Grazziutti ML, et al. Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transplant. 2006; 37(9): 857-64. doi: 10. 1038/sj. bmt. 1705340.
122. Kontoyiannis DP, Chamilos G, Lewis RE, et al. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer. 2007; 110(6): 1303-6. doi: 10. 1002/cncr. 22909.
123. Hahn T, Cummings KM, Michalek AM, Lipman BJ, Segal BH, McCarthy PL Jr. Efficacy of high-efficiency particulate air filtration in preventing aspergillosis in immunocompromised patients with hematologic malignancies. Infect Control Hosp Epidemiol. 2002; 23(9): 525-31. doi: 10. 1086/502101.
124. Blijlevens NM, Donnelly JP, De Pauw BE. Prospective evaluation of gut mucosal barrier injury following various myeloablative regimens for haematopoietic stem cell transplant. Bone Marrow Transplant. 2005; 35(7): 707-11. doi: 10. 1038/sj. bmt. 1704863.
125. Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut? Clin Infect Dis. 2001; 33(12): 1959-67. doi: 10. 1086/323759.
126. Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis. 1995; 172(4): 1035-41.
127. Menichetti F, Del Favero A, Martino P, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. Clin Infect Dis. 1999; 28(2): 250-5. doi: 10. 1086/515129.
128. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis. 1995; 171(6): 1545-52.
129. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004; 39(10): 1407-16. doi: 10. 1086/422312.
130. Miyakoshi S, Kusumi E, Matsumura T, et al. Invasive fungal infection following reduced-intensity cord blood transplantation for adult patients with hematologic diseases. Biol Blood Marrow Transplant. 2007; 13(7): 771-7. doi: 10. 1016/j. bbmt. 2007. 02. 012.
131. Rychly DJ, DiPiro JT. Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy. 2005; 25(9): 1181-92. doi: 10. 1592/phco. 2005. 25. 9. 1181.